Relacorilant
Approved, for something elseMeasured in people, not heightBy mouthSmall molecule
A more selective cortisol blocker, approved only as part of an ovarian cancer treatment in adults; the FDA turned it down for Cushing's syndrome.
A selective glucocorticoid receptor modulator with no progesterone-receptor activity. Approved by the FDA in March 2026 as Lifyorli, with nab-paclitaxel, for adults with platinum-resistant ovarian cancer. For hypertension caused by hypercortisolism the FDA declined it in December 2025, asking for more evidence that it works; a resubmission is under review.
Risks. No boxed warning, but its label warns of low white cells and serious infections, adrenal failure and harm to a pregnancy.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.